Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 versus beclometasone + formoterol in COPD
2013-001057-27Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium, beclomethasone dipropionate, formoterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change from baseline in pre-dose morning FEV1 at Week 26 and Change from baseline in 2-hour post-dose morning FEV1 at Week 26. Started Nov 2013; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumbeclomethasone dipropionateformoterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-001057-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001057-27.